High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention

European Journal of Preventive Cardiology

Volumn 20, Issue 6, 2013, Pages 922-929

  Bjerre, Mette ^a,b   Pedersen, Sune H ^c   Møgelvang, Rasmus ^d   Lindberg, Søren ^c   Jensen, Jan S ^c,e   Galatius, Søren ^c   Flyvbjerg, Allan ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Holbaek University Hospital   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

hsCRP; OPN; Osteopontin; PCI; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; CREATININE; HEPARIN; OSTEOPONTIN; TROPONIN I;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

HSCRP; OPN; OSTEOPONTIN; PCI; STEMI;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DENMARK; FEMALE; HEART FAILURE; HOSPITALS, HIGH-VOLUME; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPONTIN; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84887100788     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487313487083     Document Type: Article

References (31)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009 ; 119: e21 - e181
2. Boden WE, Gupta V. Reperfusion strategies in acute ST-segment elevation myocardial infarction. Curr Opin Cardiol. 2008 ; 23: 613-619
3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 ; 361: 13-20
4. Haahr-Pedersen S, Bjerre M, Flyvbjerg A, et al. Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention. J Invasive Cardiol. 2009 ; 21: 13-19
5. Bjerre M, Hansen TK, Flyvbjerg A. Complement activation and cardiovascular disease. Horm Metab Res. 2008 ; 40: 626-634
6. Holme I, Aastveit AH, Hammar N, et al. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis. 2010 ; 213: 299-305
7. Fisher LW, Torchia DA, Fohr B, et al. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001 ; 280: 460-465
8. Waller AH, Sanchez-Ross M, Kaluski E, et al. Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol Rev. 2010 ; 18: 125-131
9. Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009 ; 11: 206-213
10. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009 ; 3: 311-322
11. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003 ; 170: 333-337
12. Kato R, Momiyama Y, Ohmori R, et al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J. 2009 ; 73: 152-157
13. Georgiadou P, Iliodromitis EK, Kolokathis F, et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest. 2010 ; 40: 288-293
14. Madsen M, Davidsen M, Rasmussen S, et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003 ; 56: 124-130
15. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007 ; 49: 2129-2138
16. Hemingway H, Philipson P, Chen R, et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med. 2010 ; 7: e1000286 - e1000286
17. Lavie CJ, Milani RV, Verma A, et al. C-reactive protein and cardiovascular diseases - is it ready for primetime?. Am J Med Sci. 2009 ; 338: 486-492
18. Hansen TK, Gall MA, Tarnow L, et al. Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med. 2006 ; 166: 2007-2013
19. Cummings DM, King DE, Mainous AG, et al. Combining serum biomarkers: the association of C-reactive protein, insulin sensitivity, and homocysteine with cardiovascular disease history in the general US population. Eur J Cardiovasc Prev Rehabil. 2006 ; 13: 180-185
20. Hughes MF, Saarela O, Blankenberg S, et al. A multiple biomarker risk score for guiding clinical decisions using a decision curve approach. Eur J Prev Cardiol. 2012 ; 19: 874-884
21. Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001 ; 88: 1080-1087
22. Singh M, Foster CR, Dalal S, et al. Role of osteopontin in heart failure associated with aging. Heart Fail Rev. 2010 ; 15: 487-494
23. Georgiadou P, Iliodromitis EK, Kolokathis F, et al. Plasma levels of osteopontin before and 24 h after percutaneous coronary intervention. Expert Opin Ther Targets. 2008 ; 12: 1477-1480
24. Yan X, Sano M, Lu L, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2010 ; 9: 70-70
25. Lorenzen J, Kramer R, Kliem V, et al. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest. 2010 ; 40: 294-300
26. Jugdutt BI, Palaniyappan A, Uwiera RR, Idikio H. Role of healing-specific-matricellular proteins and matrix metalloproteinases in age-related enhanced early remodeling after reperfused STEMI in dogs. Mol Cell Biochem. 2009 ; 322: 25-36
27. Singh M, Ananthula S, Milhorn DM, et al. Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front Biosci. 2007 ; 12: 214-221
28. Myers DL, Harmon KJ, Lindner V, et al. Alterations of arterial physiology in osteopontin-null mice. Arterioscler Thromb Vasc Biol. 2003 ; 23: 1021-1028
29. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem. 2000 ; 275: 20197-20203
30. Kato R, Momiyama Y, Ohmori R, et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2006 ; 26: e1 - e2
31. Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012 ; 98: 683-690